MAP4K1 expression is a novel resistance mechanism and independent prognostic marker in AML-but can be overcome via targeted inhibition.

Knight, Tristan E; Edwards, Holly; Taub, Jeffrey W; Ge, Yubin

Knight, Tristan E; Edwards, Holly; Taub, Jeffrey W; Ge, Yubin.

Afiliación

Knight TE; Division of Hematology/Oncology, Department of Pediatrics, The Hospital for Sick Children (SickKids) and The University of Toronto, Toronto, Ontario, Canada.
Edwards H; Department of Oncology, Wayne State University School of Medicine, 421 East Canfield, Detroit, MI 48201, USA; Molecular Therapeutics Program, Barbara Ann Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, MI, USA.
Taub JW; Molecular Therapeutics Program, Barbara Ann Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, MI, USA; Department of Pediatrics, Wayne State University School of Medicine, Detroit, MI, USA; Division of Pediatric Hematology and Oncology, Department of Pediatrics, Children
Ge Y; Department of Oncology, Wayne State University School of Medicine, 421 East Canfield, Detroit, MI 48201, USA; Molecular Therapeutics Program, Barbara Ann Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, MI, USA. Electronic address: gey@karmanos.org.

EBioMedicine ; 70: 103488, 2021 08.

Article en En | MEDLINE | ID: mdl-34280781

Asunto(s)

Resistencia a Antineoplásicos; Leucemia Mieloide Aguda; Humanos; Pronóstico

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Leucemia Mieloide Aguda / Resistencia a Antineoplásicos Tipo de estudio: Prognostic_studies Límite: Humans Idioma: En Revista: EBioMedicine Año: 2021 Tipo del documento: Article País de afiliación: Canadá

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google